Citadel Advisors
MRKR icon

Citadel Advisors’s Marker Therapeutics MRKR Stock Holding History

Citadel Advisors’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,120
Closed -$5K – 13654
2022
Q1 		$5K Sell
1,120
-1,200
-52% -$6.86K ﹤0.01% 13425
2021
Q4 		$22K Sell
2,320
-150
-6% -$1.99K ﹤0.01% 13562
2021
Q3 		$42K Sell
2,470
-2,280
-48% -$46.7K ﹤0.01% 13456
2021
Q2 		$133K Sell
4,750
-16,980
-78% -$447K ﹤0.01% 12639
2021
Q1 		$487K Buy
+21,730
New +$497K ﹤0.01% 9733
2020
Q3 		– Sell
-1,040
Closed -$22K – 10488
2020
Q2 		$22K Buy
+1,040
New +$22.7K ﹤0.01% 9534
2019
Q4 		– Sell
-1,930
Closed -$99K – 9505
2019
Q3 		$99K Buy
1,930
+660
+52% +$39K ﹤0.01% 8485
2019
Q2 		$101K Buy
+1,270
New +$75.4K ﹤0.01% 8527

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Citadel Advisors's MRKR Position: Q1 2026 in Review

Citadel Advisors sold out of Marker Therapeutics (MRKR) in Q1 2026, closing a stake of 58,847 shares — an estimated $87.7K sold.

Citadel Advisors first reported a position in MRKR in Q3 2019 and held it in 12 quarters. The position peaked at $817K in Q2 2021. 35 funds tracked by Wall St. Rank hold MRKR as of Q1 2026.

  • Citadel Advisors reported no remaining Marker Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 58,847 Marker Therapeutics shares in Q1 2026, an estimated $87.7K.
  • Citadel Advisors first reported a position in Marker Therapeutics in Q3 2019 and held it in 12 quarters.
  • Citadel Advisors's Marker Therapeutics position peaked at $817K in Q2 2021.
  • 35 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.